TABLE 3.
Adverse events with an overall rate of ≥10%
| Adverse event | Data (no. [%]) for: |
|||||
|---|---|---|---|---|---|---|
| Subjects receiving XOMA 3AB at a dosage (mg/kg) of: |
Subjects receiving placebo (combined) (n = 6) | All subjects (n = 24) | ||||
| 0.033 (n = 6) | 0.165 (n = 6) | 0.330 (n = 6) | Combined (n = 18) | |||
| Blood glucose increased | 1 (16.7) | 3 (50.0) | 1 (16.7) | 5 (27.8) | 4 (66.7) | 9 (37.5) |
| Headache | 3 (50.0) | 3 (50.0) | 1 (16.7) | 7 (38.9) | 1 (16.7) | 8 (33.3) |
| Nasopharyngitis | 1 (16.7) | 4 (66.7) | 0 (0) | 5 (27.8) | 1 (16.7) | 6 (25.0) |
| ALT increased | 1 (16.7) | 0 (0) | 2 (33.3) | 3 (16.7) | 2 (33.3) | 5 (20.8) |
| AST increased | 1 (16.7) | 0 (0) | 1 (16.7) | 2 (11.1) | 2 (33.3) | 4 (16.7) |
| Hemoglobin decreased | 1 (16.7) | 1 (16.7) | 1 (16.7) | 3 (16.7) | 1 (16.7) | 4 (16.7) |
| Upper respiratory tract infection | 0 (0) | 1 (16.7) | 1 (16.7) | 2 (11.1) | 2 (33.3) | 4 (16.7) |
| CO2 decreased | 1 (16.7) | 1 (16.7) | 1 (16.7) | 3 (16.7) | 0 (0) | 3 (12.5) |
| Muscle strain | 0 (0) | 0 (0) | 2 (33.3) | 2 (11.1) | 1 (16.7) | 3 (12.5) |
| Myalgia | 0 (0) | 0 (0) | 2 (33.3) | 2 (11.1) | 1 (16.7) | 3 (12.5) |